Mucosis

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.